Sir, Vibrio parahaemolyticus is a marine microorganism, frequently isolated from seafood, at water temperatures above 15 C. 1 It is also a foodborne pathogen, often linked to consumption of raw or uncooked seafood, mostly encountered in patients in Asia or the USA.
Sir, Vibrio parahaemolyticus is a marine microorganism, frequently isolated from seafood, at water temperatures above 15 C. 1 It is also a foodborne pathogen, often linked to consumption of raw or uncooked seafood, mostly encountered in patients in Asia or the USA. 1 Ingestion of V. parahaemolyticus-contaminated seafood can lead to gastroenteritis. Symptoms are abdominal cramps, nausea, diarrhoea, fever, headache and chills. 1 In most cases, V. parahaemolyticus infections are self-limiting but, in patients with underlying diseases, V. parahaemolyticus can cause septicaemia. 1 To treat severe or prolonged infections, antibiotics such as fluoroquinolones, azithromycin or rifaximin can be prescribed. 2 WT V. parahaemolyticus are characterized as being susceptible to all antibiotic classes, except penicillins. 3 V. parahaemolyticus strain 16-B3PA-006 was isolated in January 2016, from a shelled shrimp tail imported from Vietnam to France. Antimicrobial susceptibility was tested by the disc diffusion method (Bio-Rad, Marne-La-Coquette, France), following CLSI recommendations. 4 Genomic characterization of the isolate was performed by WGS on a NextSeq (Illumina, San Diego, CA, USA). The raw reads were trimmed (minimum length, 35 bp; quality score, 0.03) and assembled in CLC Genomics Workbench 7.5.1, firstly by mapping chromosome 1 and 2 from the V. parahaemolyticus reference genome (V. parahaemolyticus RIMD 2210633) and then de novo assembly of the remaining paired-end reads. A total of 190 contigs were obtained including 60 contigs that did not map the reference genome, indicating the presence of acquired genetic material. The Center for Genomic Epidemiology server (https://cge.cbs.dtu.dk/serv ices/) was used to identify acquired antimicrobial resistance genes (Resfinder), plasmid presence (PlasmidFinder) and ST (MLST).
Strain 16-B3PA-006 was assigned to V. parahaemolyticus ST-864. PlasmidFinder identified a unique IncA/C2 plasmid. V. parahaemolyticus strain 16-B3PA-006 was phenotypically resistant to amoxicillin/clavulanate, cefoxitin, cefotaxime, ceftazidime, cefuroxime, cefepime and trimethoprim/sulfamethoxazole, but remained susceptible to imipenem, tetracycline, ciprofloxacin and gentamicin. Resfinder identified with 100% identity the resistance genes bla NDM-1 , sul1, sul2, dfrA16, strA, strB and aadA2. Moreover, floR and tet(A) were detected with 98.19% and 99.83% identity, respectively. No resistance gene was neighbouring bla NDM-1 , only sul1 was on the opposite side of the contig, at a distance of 14 kb. A Blastn analysis of this contig with the National Center for Biotechnology Information nucleotide database identified a part of transposon Tn125: DISAba125, bla NDM-1 , ble, trpF, tat, dct, groS, groL and IS91. Despite the apparent susceptibility to imipenem, the carbapenem inactivation method result was positive, confirming carbapenemase production by this strain. 5 Even if the chromosomal or plasmidic location of bla NDM-1 had not been assessed so far, the carbapenemase phenotype had been successfully transferred to Escherichia coli UB5201 strain by conjugation assay.
V. parahaemolyticus 16-B3PA-006 was confirmed to be MDR, by both genotype and phenotype, being resistant to more than three antibiotic classes: b-lactams, folate pathway inhibitors, phenicols, aminoglycosides and tetracyclines. The Tn125 transposon, carried by strain 16-B3PA-006, has been partially described in a clinical case of Vibrio fluvialis, but the transposon was not complete. 6 Since its first description in 2009 in a patient returning from India, NDM-1 has been described in almost all parts of the world and is considered as one of the most clinically significant carbapenemases. 7 In many of the first cases reported, patients were reporting recent inter-country travel history, not only to the Indian subcontinent, but also to the Balkan states, the Arabian Peninsula and North Africa; some of them having been repatriated for medical purposes. 7 NDM-1-producing Vibrio spp. have been reported to a lesser extent in V. fluvialis and Vibrio cholerae clinical or environmental samples. 6, [8] [9] [10] To our knowledge, this report is the first description of a V. parahaemolyticus strain producing NDM-1 isolated from a food item. Other carbapenemase-producing bacteria isolated from foodstuffs have already been reported: NDM-1-producing Salmonella and Enterobacter cloacae from chicken and clam; and VIM-1-producing Salmonella and E. coli from pork and Venus clam. [11] [12] [13] [14] Nicol et al. 12 and Roschanski et al. 14 highlighted that the sampled food products in their studies were also imported.
Interestingly, strain 16-B3PA-006 was proved to both carry the bla NDM-1 gene and display in vitro carbapenemase activity; nonetheless, the antibiogram categorized it as clinically susceptible to imipenem according to CLSI criteria. In vitro susceptibility to any carbapenem had not been described previously in NDM-1-producing Vibrio spp. 6, [8] [9] [10] Clinical microbiologists should be aware that NDM-1 carbapenemase activity in V. parahaemolyticus might be challenging to evidence through routine susceptibility tests.
It is generally assumed that travellers, colonized by carbapenemase-producing bacteria, import it from endemic to non-endemic parts of the world. 15 However, imported food should also be taken into consideration as a potential vector of dissemination of clinically significant carbapenemases such as NDM-1. The role of the global food trade should certainly not be underestimated anymore as an alternative route for carbapenemase dissemination.
Nucleotide sequence accession number
Strain 16-B3PA-006 sequence is available under GenBank accession number PETB00000000.
Sir, Over the last decades, MDR Gram-negative bacilli have emerged as an important aetiological agent of nosocomial-acquired infections worldwide. The combination of b-lactam and new b-lactamases inhibitors has become an option for treating those
